Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs
- PMID: 4966657
- PMCID: PMC1409286
Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs
Abstract
The in vitro cytotoxic effect of spleen cells of mice immunized by tumour allografts was studied by measuring target cell inactivation as a function of release of radioactive label (51Cr) or loss of cloning efficiency. When sensitized lymphoid cells were incubated with target cells at a ratio of 100:1, up to 90 per cent of the incorporated label was released within 6–9 hours, while the number of clone-forming cells was reduced by up to 99 per cent in the same time period. Isoantiserum from the graft recipients, as well as its 19S and 7S fractions, protected target cells against the toxic effect of the spleen cells, but a lipoprotein antigen isolated from the tumour cells failed to inhibit the cytotoxic reaction. Target cell lysis as measured by specific release of 51Cr was partially inhibited by actinomycin-D and by cycloheximide at concentrations which effectively blocked DNA-dependent RNA and protein synthesis.
Similar articles
-
Lymphocyte-antibody interactions in immunological enhancement.Transplant Proc. 1969 Mar;1(1):530-4. Transplant Proc. 1969. PMID: 5406837 No abstract available.
-
Lymphocyte sequestration: its possible role in tumor immunity.Transplant Proc. 1973 Mar;5(1):969-73. Transplant Proc. 1973. PMID: 4633096 No abstract available.
-
Interaction of isoantibody and cytotoxic lymphocytes with allogeneic tumor cells.J Immunol. 1974 Jul;113(1):279-88. J Immunol. 1974. PMID: 4208919 No abstract available.
-
Quantitation of the cell-mediated immune response. I. The number of cytolytically active mouse lymphoid cells induced by immunization with allogeneic mastocytoma cells.J Immunol. 1971 Dec;107(6):1558-66. J Immunol. 1971. PMID: 5000987 No abstract available.
-
Central inhibition of cellular immunity to leukemia L1210 by isoantibody.Cancer Res. 1972 Apr;32(4):825-31. Cancer Res. 1972. PMID: 4622583 No abstract available.
Cited by
-
TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges.J Transl Med. 2024 Oct 4;22(1):897. doi: 10.1186/s12967-024-05703-9. J Transl Med. 2024. PMID: 39367419 Free PMC article. Review.
-
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy.Cancers (Basel). 2020 Jul 2;12(7):1757. doi: 10.3390/cancers12071757. Cancers (Basel). 2020. PMID: 32630618 Free PMC article.
-
Natural Killer (NK) Cell Expression of CD2 as a Predictor of Serial Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC).Antibodies (Basel). 2020 Oct 16;9(4):54. doi: 10.3390/antib9040054. Antibodies (Basel). 2020. PMID: 33081115 Free PMC article.
-
Detection of Virus-Specific CD8+ T Cells With Cross-Reactivity Against Alloantigens: Potency and Flaws of Present Experimental Methods.Transplant Direct. 2015 Nov 4;1(10):e40. doi: 10.1097/TXD.0000000000000550. eCollection 2015 Nov. Transplant Direct. 2015. PMID: 27500209 Free PMC article.
-
The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.Virology. 2021 Jul;559:1-9. doi: 10.1016/j.virol.2021.03.009. Epub 2021 Mar 19. Virology. 2021. PMID: 33774551 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources